Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)

NCT01064505 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT01064505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01064505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2010
Completion date
April 30, 2013
Enrollment
48 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

non-arteritic anterior ischemic optic neuropathy, optic atrophy